Access to optimal cancer care can be secured for every patient by a proper understanding of the patient’s magnitude of clinical effects. Professor Solange Peters who is a scientific chair said, “ESMO 2018 is first and foremost about innovation, and compelling clinical trial data will be presented about potential new treatments for breast, prostate, ovarian and other cancers. But the conference is also about integration and sustainability, and we are encouraging a more integrated approach to cancer care as well as supporting essential policy-informing discussions about affordable, sustainable models of care.”
A study found that authorities of health generally made decisions quicker for the drugs with the highest benefit on the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) that uses a consistent, structured, and rational approach to grade the clinical profits that could be presumed from anti-cancer treatments.
ESMO president Josep Taberno said, “ESMO is a driver of change affecting the entire field of oncology. ESMO-MCBS and ESCAT are grounding treatment choices in the best available evidence, helping to enhance decision making for both clinicians and healthcare providers, and making a major contribution to securing access to optimal cancer care for all patients, wherever they live.”